2,671.10
+3.13%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Glenmark Pharmaceuticals
Its shares trade on NSE under the ticker GLENMARK.NS. It has been listed since 10 December 1999. In the fiscal year to 31 March 2026, it reported revenue of ₹167.11bn and net income of ₹13.62bn. At that date it held total assets of ₹199.08bn and shareholders' equity of ₹105.12bn.
Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. The company focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. The company is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. The company is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Dec 1999
- Employees
- 15,415
- Website
- glenmarkpharma.com ↗
Leadership
Pay as last reported
- Mr. Glenn SaldanhaExecutive Chairman of the Board, Managing Director, since 1998₹168.6m
- Mr. V. S. ManiGlobal Chief Financial Officer, Executive Director, since 2017₹102.1m
- Mr. Harish KuberCompliance Officer, Company Secretary₹5.7m
- Mrs. Cherylann PintoExecutive Director - Corporate Services₹60.8m
- Mrs. Blanche SaldanhaNon-Executive Director, since 1982₹600,000
- Mr. Dipankar BhattacharjeeNon-Executive Independent Director₹1.1m
- Mr. Rajesh DesaiNon-Executive Independent Director, since 2020₹1.9m
- Mrs. Vijayalakshmi IyerNon-Executive Independent Director₹1.2m
- Ms. Sona RamasastryNon-Executive Independent Director₹1.4m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 71
- Environment
- 70
- Social
- 76
- Governance
- 68
- Direct emissions (scope 1)
- 15,455 t
- Energy emissions (scope 2)
- 69,632 t
- Value chain emissions (scope 3)
- 171,146 t
- Women in the workforce
- 14%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong presence in the pharmaceutical industry with a diverse product portfolio.
- Robust research and development capabilities, leading to innovative products.
- Well-established manufacturing facilities ensuring high-quality production.
- Extensive distribution network, reaching both domestic and international markets.
Weaknesses
- Dependence on a limited number of key products, increasing vulnerability.
- Relatively high debt levels, potentially impacting financial flexibility.
- Lack of geographic diversification, with majority operations in India.
Opportunities
- Growing demand for generic drugs and biosimilars globally.
- Expansion into emerging markets, offering untapped growth potential.
- Increasing focus on digital healthcare and telemedicine, providing new avenues for customer engagement.
Threats
- Intense competition from both domestic and international pharmaceutical companies.
- Stringent regulatory environment impacting product approvals and timelines.
- Pricing pressures in the generic drugs market, affecting profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.